ACR/ARHP 2016 Annual Meeting
Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study
ACR/ARHP Annual Meeting 2015
According to study results presented at the 2015 ACR/ARHP Annual Meeting, initiating non-TNF inhibitor monotherapy had similar or better efficacy compared with initiation of TNF inhibitor monotherapy in patients with rheumatoid arthritis.
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.